Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Landos Biopharma Inc.
Headquarters: Blacksburg, VA, United States of America
Website: N/A
Year Founded: 2017
Status: Acquired
BioCentury | Mar 26, 2024
Deals
Deals Report: Week’s M&A includes AZ-Fusion, Novo Nordisk-Cardior
Plus: Intellia deciding to step back from co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization
BioCentury | Mar 22, 2023
Finance
March 22 Quick Takes: GordonMD, Pfizer Ventures lead Flare’s $123M B round
Plus: FDA approvals for Cidara, Incyte and updates from Karuna, Astellas, NImmune, AbbVie, Roche, Lilly
BioCentury | Apr 26, 2022
Finance
Bear market returns Perceptive to its roots in distressed assets
The firm is back to picking stocks in a down market, but benefiting from years of diversification
BioCentury | Jan 6, 2022
Management Tracks
RTW levels up by adding Maraganore, promoting company creator Fong
In latest ‘retirement’ post, John Maraganore joins the team of an early Alnylam investor to help guide the firm’s next-gen portfolio companies
BioCentury | Nov 10, 2021
Management Tracks
Wandeler to leave MorphoSys
Plus: Rubius, AstraZeneca, Landos, Nyxoah, Progenity and more
BioCentury | Jun 3, 2021
Deals
Cross-border play LianBio’s ninth in-licensed therapy comes via Lyra to build out inflammatory pillar
LianBio’s fifth in-licensing deal since its launch last year adds a third anti-inflammatory from U.S. biotech Lyra to the Perceptive Advisors-backed cross-border company’s pipeline,
BioCentury | May 17, 2021
Deals
From seed to market, Landos finds a partner in Perceptive
Deal with LianBio is at least the fourth with a Perceptive affiliate
BioCentury | May 13, 2021
Finance
Latest Garabedian-led Perceptive Xontogeny fund to deploy $515M in search of ‘transformational’ assets
New fund 2x the size of debut venture vehicle
BioCentury | Feb 4, 2021
Finance
Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets
While Sana’s massive IPO drew most of the attention among new listings Thursday, biotechs Sensei and Landos made quieter NASDAQ debuts, with several more companies set to price for
BioCentury | Feb 4, 2021
Finance
Sana puts the pieces together, prices IPO that could soon be largest ever for a biotech
Cell and gene therapy tech aggregator has already raised biggest IPO in history by a preclinical biotech
Items per page:
1 - 10 of 18